Reviewing the ketamine model for schizophrenia

The observation that antagonists of the N-methyl-D-aspartate receptor (NMDAR), such as phencyclidine (PCP) and ketamine, transiently induce symptoms of acute schizophrenia had led to a paradigm shift from dopaminergic to glutamatergic dysfunction in pharmacological models of schizophrenia. The gluta...

Full description

Saved in:
Bibliographic Details
Published inJournal of psychopharmacology (Oxford) Vol. 28; no. 4; p. 287
Main Authors Frohlich, Joel, Van Horn, John D
Format Journal Article
LanguageEnglish
Published United States 01.04.2014
Subjects
Online AccessGet more information

Cover

Loading…
Abstract The observation that antagonists of the N-methyl-D-aspartate receptor (NMDAR), such as phencyclidine (PCP) and ketamine, transiently induce symptoms of acute schizophrenia had led to a paradigm shift from dopaminergic to glutamatergic dysfunction in pharmacological models of schizophrenia. The glutamate hypothesis can explain negative and cognitive symptoms of schizophrenia better than the dopamine hypothesis, and has the potential to explain dopamine dysfunction itself. The pharmacological and psychomimetic effects of ketamine, which is safer for human subjects than phencyclidine, are herein reviewed. Ketamine binds to a variety of receptors, but principally acts at the NMDAR, and convergent genetic and molecular evidence point to NMDAR hypofunction in schizophrenia. Furthermore, NMDAR hypofunction can explain connectional and oscillatory abnormalities in schizophrenia in terms of both weakened excitation of inhibitory γ-aminobutyric acidergic (GABAergic) interneurons that synchronize cortical networks and disinhibition of principal cells. Individuals with prenatal NMDAR aberrations might experience the onset of schizophrenia towards the completion of synaptic pruning in adolescence, when network connectivity drops below a critical value. We conclude that ketamine challenge is useful for studying the positive, negative, and cognitive symptoms, dopaminergic and GABAergic dysfunction, age of onset, functional dysconnectivity, and abnormal cortical oscillations observed in acute schizophrenia.
AbstractList The observation that antagonists of the N-methyl-D-aspartate receptor (NMDAR), such as phencyclidine (PCP) and ketamine, transiently induce symptoms of acute schizophrenia had led to a paradigm shift from dopaminergic to glutamatergic dysfunction in pharmacological models of schizophrenia. The glutamate hypothesis can explain negative and cognitive symptoms of schizophrenia better than the dopamine hypothesis, and has the potential to explain dopamine dysfunction itself. The pharmacological and psychomimetic effects of ketamine, which is safer for human subjects than phencyclidine, are herein reviewed. Ketamine binds to a variety of receptors, but principally acts at the NMDAR, and convergent genetic and molecular evidence point to NMDAR hypofunction in schizophrenia. Furthermore, NMDAR hypofunction can explain connectional and oscillatory abnormalities in schizophrenia in terms of both weakened excitation of inhibitory γ-aminobutyric acidergic (GABAergic) interneurons that synchronize cortical networks and disinhibition of principal cells. Individuals with prenatal NMDAR aberrations might experience the onset of schizophrenia towards the completion of synaptic pruning in adolescence, when network connectivity drops below a critical value. We conclude that ketamine challenge is useful for studying the positive, negative, and cognitive symptoms, dopaminergic and GABAergic dysfunction, age of onset, functional dysconnectivity, and abnormal cortical oscillations observed in acute schizophrenia.
Author Frohlich, Joel
Van Horn, John D
Author_xml – sequence: 1
  givenname: Joel
  surname: Frohlich
  fullname: Frohlich, Joel
  organization: 1UCLA Center for Autism Research and Treatment (CART), University of California, Los Angeles, CA, USA
– sequence: 2
  givenname: John D
  surname: Van Horn
  fullname: Van Horn, John D
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24257811$$D View this record in MEDLINE/PubMed
BookMark eNo1jktLxDAURoMozkP3riR_oGNy817KoKMwIIiuh7S510anD9qq6K93QF19m8M534Idt12LjF1IsZLSuSsBNngvpVRGQhDhiM2ltrJw4M2MLcbxVQhptTWnbAYajDuwc7Z6xI-Mn7l94VON_A2n2OQWedMl3HPqBj5Wdf7u-nrANsczdkJxP-L53y7Z8-3N0_qu2D5s7tfX26IyOkxFBNQxVnjIABElA0aR0k6IqozBByhV8jaWZbKEgKEKjgI5S2BS8opgyS5_vf172WDa9UNu4vC1-z8OP47xRZM
CitedBy_id crossref_primary_10_1093_schbul_sby190
crossref_primary_10_1097_FBP_0000000000000354
crossref_primary_10_3390_ijms23115968
crossref_primary_10_1016_j_biopha_2018_07_030
crossref_primary_10_1080_00952990_2018_1559849
crossref_primary_10_3389_fnins_2023_1177428
crossref_primary_10_1016_j_bbr_2022_113925
crossref_primary_10_1016_j_neuropharm_2016_10_002
crossref_primary_10_30756_ahmj_2023_10_01
crossref_primary_10_1038_s42003_023_04988_8
crossref_primary_10_1080_15592294_2024_2417158
crossref_primary_10_1007_s00213_022_06121_9
crossref_primary_10_1016_j_jpsychires_2021_08_010
crossref_primary_10_3390_ijms23105482
crossref_primary_10_3390_molecules24213993
crossref_primary_10_3389_fpsyt_2021_679960
crossref_primary_10_1016_j_pnpbp_2022_110560
crossref_primary_10_1016_j_euroneuro_2015_04_012
crossref_primary_10_3389_fnbeh_2020_00029
crossref_primary_10_3390_ph17040461
crossref_primary_10_1007_s00213_015_3946_6
crossref_primary_10_1016_j_bbr_2023_114614
crossref_primary_10_1093_ijnp_pyaa042
crossref_primary_10_1523_JNEUROSCI_1121_22_2022
crossref_primary_10_1016_j_clinph_2017_06_246
crossref_primary_10_1038_s41386_019_0328_5
crossref_primary_10_1016_j_neuroscience_2018_01_021
crossref_primary_10_1007_s00213_022_06090_z
crossref_primary_10_1111_ajad_12984
crossref_primary_10_1016_j_jpsychires_2016_09_017
crossref_primary_10_1016_j_schres_2016_09_008
crossref_primary_10_1016_j_nlm_2021_107396
crossref_primary_10_3390_ijms24031913
crossref_primary_10_1016_j_pbb_2021_173287
crossref_primary_10_1016_j_nicl_2019_101739
crossref_primary_10_1007_s40138_019_00177_2
crossref_primary_10_1016_j_neuroscience_2020_09_029
crossref_primary_10_1038_mp_2017_6
crossref_primary_10_1186_s13104_022_06219_5
crossref_primary_10_1016_j_neuroscience_2015_06_059
crossref_primary_10_1016_j_bbr_2022_113964
crossref_primary_10_1016_j_biopha_2018_04_082
crossref_primary_10_1016_j_neuropharm_2024_110088
crossref_primary_10_1038_npp_2016_17
crossref_primary_10_1007_s00210_018_1552_y
crossref_primary_10_1186_s13063_018_2831_0
crossref_primary_10_1002_hup_2738
crossref_primary_10_1016_j_physbeh_2015_05_013
crossref_primary_10_1007_s12031_020_01502_1
crossref_primary_10_1007_s00213_016_4401_z
crossref_primary_10_3389_fnins_2022_1001869
crossref_primary_10_1007_s00213_015_4175_8
crossref_primary_10_17116_jnevro2021121091131
crossref_primary_10_1016_j_comppsych_2019_152122
crossref_primary_10_1016_j_neulet_2020_134984
crossref_primary_10_1007_s00406_023_01629_3
crossref_primary_10_1167_jov_21_6_9
crossref_primary_10_1016_j_neuropharm_2021_108896
crossref_primary_10_1016_j_pbb_2019_04_002
crossref_primary_10_1016_j_neuropharm_2018_01_005
crossref_primary_10_3389_fpsyt_2022_997758
crossref_primary_10_3390_jcm11071845
crossref_primary_10_1016_j_pnpbp_2023_110913
crossref_primary_10_1523_ENEURO_0406_22_2023
crossref_primary_10_1016_j_brainresbull_2021_07_004
crossref_primary_10_1016_j_bbr_2024_115231
crossref_primary_10_1016_j_schres_2015_11_006
crossref_primary_10_1080_17512433_2025_2459377
crossref_primary_10_1007_s12264_020_00507_5
crossref_primary_10_1155_2023_9093231
crossref_primary_10_1097_ALN_0000000000001513
crossref_primary_10_3389_fnins_2020_590088
crossref_primary_10_1007_s00204_021_03024_0
crossref_primary_10_1177_0269881118822263
crossref_primary_10_3389_fpsyt_2017_00037
crossref_primary_10_3389_fncir_2021_769969
crossref_primary_10_1016_j_psychres_2020_112938
crossref_primary_10_1097_FBP_0000000000000327
crossref_primary_10_1016_j_neuropharm_2022_108947
crossref_primary_10_1016_j_neubiorev_2018_07_001
crossref_primary_10_1186_s12868_015_0149_3
crossref_primary_10_1007_s00702_019_02081_1
crossref_primary_10_1016_j_jpsychires_2016_06_013
crossref_primary_10_1016_j_jpsychires_2016_12_003
crossref_primary_10_1016_j_imed_2022_03_001
crossref_primary_10_1038_s41386_024_01895_2
crossref_primary_10_1016_j_neuropharm_2018_06_008
crossref_primary_10_1016_j_psychres_2018_05_050
crossref_primary_10_1007_s43440_021_00232_4
crossref_primary_10_1016_j_neuroimage_2022_119624
crossref_primary_10_1016_j_neuropharm_2024_109970
crossref_primary_10_1177_0269881114553647
crossref_primary_10_3390_biomedicines13030649
crossref_primary_10_1007_s00702_024_02793_z
crossref_primary_10_1111_bph_15487
crossref_primary_10_1016_j_biopha_2018_06_043
crossref_primary_10_1016_j_bbr_2024_115214
crossref_primary_10_1016_j_euroneuro_2015_04_004
crossref_primary_10_1162_CPSY_a_00005
crossref_primary_10_1177_0269881117748903
crossref_primary_10_23736_S2724_6612_21_02068_9
crossref_primary_10_3389_fnbeh_2017_00181
crossref_primary_10_1016_j_psychres_2016_01_023
crossref_primary_10_1097_FBP_0000000000000585
crossref_primary_10_3389_fpsyt_2022_737295
crossref_primary_10_1038_s41598_023_38258_8
crossref_primary_10_3390_ijms22179309
crossref_primary_10_1016_j_neuropharm_2020_108129
crossref_primary_10_1016_j_cortex_2016_03_017
crossref_primary_10_1016_j_pnpbp_2018_05_014
crossref_primary_10_1007_s00702_019_02080_2
crossref_primary_10_1080_14737175_2016_1174577
crossref_primary_10_1002_hup_2656
crossref_primary_10_1016_j_neuroscience_2020_05_012
crossref_primary_10_1186_s41983_023_00719_2
crossref_primary_10_1016_j_mehy_2016_05_032
crossref_primary_10_1016_j_neuroimage_2022_119004
crossref_primary_10_1016_j_acthis_2020_151531
crossref_primary_10_1016_j_phrs_2024_107085
crossref_primary_10_1016_j_neuint_2019_104503
crossref_primary_10_3389_fphar_2016_00348
crossref_primary_10_3389_fpsyt_2022_1017504
crossref_primary_10_1016_j_psychres_2021_114231
crossref_primary_10_3934_Neuroscience_2014_2_169
crossref_primary_10_1007_s00221_019_05556_5
crossref_primary_10_1016_j_schres_2019_11_041
crossref_primary_10_1016_j_cpr_2022_102231
crossref_primary_10_1016_j_pharmthera_2020_107520
crossref_primary_10_1016_j_schres_2020_06_028
crossref_primary_10_1051_jbio_2023028
crossref_primary_10_1097_NNR_0000000000000197
crossref_primary_10_2139_ssrn_3926148
crossref_primary_10_5607_en_2017_26_1_11
crossref_primary_10_1152_japplphysiol_00476_2020
crossref_primary_10_1016_j_bja_2018_01_022
crossref_primary_10_1021_acsptsci_4c00133
crossref_primary_10_1016_j_neuropharm_2016_01_035
crossref_primary_10_7554_eLife_56151
crossref_primary_10_1038_s41380_020_00878_1
crossref_primary_10_1016_j_coph_2014_11_006
crossref_primary_10_1038_s41380_021_01082_5
crossref_primary_10_1093_brain_awab095
crossref_primary_10_1371_journal_pone_0236363
crossref_primary_10_1016_j_neuroscience_2023_10_008
crossref_primary_10_1038_tp_2015_151
crossref_primary_10_1016_j_physbeh_2022_113708
crossref_primary_10_1016_j_pnpbp_2017_10_009
crossref_primary_10_3389_fpsyt_2021_671007
crossref_primary_10_3390_ijms21218048
crossref_primary_10_2174_2210303109666190619103230
crossref_primary_10_26599_BSA_2018_2018_9050009
crossref_primary_10_1016_j_heliyon_2024_e38986
crossref_primary_10_1007_s11011_021_00821_5
crossref_primary_10_1038_s41380_020_0793_6
crossref_primary_10_7554_eLife_53664
crossref_primary_10_1016_j_pnpbp_2020_110060
crossref_primary_10_1016_j_jbtep_2023_101891
crossref_primary_10_1016_j_schres_2020_09_013
crossref_primary_10_1111_ejn_14853
crossref_primary_10_3389_fpsyt_2017_00292
crossref_primary_10_1016_j_biopha_2021_112369
crossref_primary_10_1111_jnc_16133
crossref_primary_10_3389_fncel_2019_00499
crossref_primary_10_1016_j_ibneur_2023_12_012
crossref_primary_10_1016_j_bbr_2025_115441
crossref_primary_10_3390_brainsci13060848
crossref_primary_10_1016_j_pneurobio_2025_102718
crossref_primary_10_1371_journal_pcbi_1009280
crossref_primary_10_1007_s11682_014_9339_3
crossref_primary_10_1002_hbm_23294
crossref_primary_10_1016_j_biopsych_2019_07_011
crossref_primary_10_1016_j_pbb_2023_173658
crossref_primary_10_1016_j_neuroscience_2021_08_004
crossref_primary_10_1038_s41398_023_02344_2
crossref_primary_10_1038_s41467_024_48664_9
crossref_primary_10_1111_acem_13725
crossref_primary_10_3390_ijms23147800
crossref_primary_10_1007_s00213_019_05366_1
crossref_primary_10_1097_FBP_0000000000000289
crossref_primary_10_1111_ejn_14756
crossref_primary_10_3389_fnsys_2015_00190
crossref_primary_10_1177_02698811231187339
crossref_primary_10_1016_j_lfs_2020_117535
crossref_primary_10_1007_s00213_017_4807_2
crossref_primary_10_1002_cpt_3420
crossref_primary_10_1016_j_nicl_2018_09_001
crossref_primary_10_1371_journal_pone_0186732
crossref_primary_10_1016_j_brainresbull_2022_12_006
crossref_primary_10_1016_j_nlm_2020_107319
crossref_primary_10_1016_j_nicl_2018_05_037
crossref_primary_10_3389_fnsys_2022_963691
crossref_primary_10_1111_cns_14464
crossref_primary_10_1515_revneuro_2019_0090
crossref_primary_10_3389_fphar_2021_746935
crossref_primary_10_1007_s12264_018_0208_8
crossref_primary_10_1016_j_biopha_2023_114318
crossref_primary_10_1111_bph_13222
crossref_primary_10_1002_hbm_24838
crossref_primary_10_1016_j_schres_2016_10_027
crossref_primary_10_1177_23982128211055426
crossref_primary_10_1038_tp_2015_111
crossref_primary_10_3389_fpsyt_2021_786622
crossref_primary_10_3390_brainsci11070917
crossref_primary_10_1016_j_physbeh_2017_07_016
crossref_primary_10_1016_j_ajp_2024_104199
crossref_primary_10_1016_j_biopsych_2020_09_001
crossref_primary_10_3390_brainsci14121281
crossref_primary_10_3389_fnbeh_2022_1057319
crossref_primary_10_1007_s00406_024_01865_1
crossref_primary_10_1016_j_bbr_2020_112629
crossref_primary_10_3389_fnins_2019_00138
crossref_primary_10_3389_fnbeh_2016_00226
crossref_primary_10_1016_j_ntt_2022_107079
crossref_primary_10_1038_tp_2017_198
crossref_primary_10_1016_j_ejphar_2016_05_026
crossref_primary_10_1017_S1461145714000959
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1177/0269881113512909
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Psychology
Pharmacy, Therapeutics, & Pharmacology
EISSN 1461-7285
ExternalDocumentID 24257811
Genre Review
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIBIB NIH HHS
  grantid: U54 EB005149
– fundername: NINDS NIH HHS
  grantid: R41 NS081792
– fundername: NINDS NIH HHS
  grantid: R41NS081792
– fundername: NIBIB NIH HHS
  grantid: 2U54EB005149
– fundername: NIBIB NIH HHS
  grantid: P41 EB015922
GroupedDBID ---
-TM
-~X
.2E
.2F
.2G
.2J
.2N
01A
0R~
1~K
29L
31R
31S
31U
31X
31Y
31Z
4.4
53G
54M
5GY
5VS
6PF
85S
AABMB
AABOD
AACKU
AACMV
AACTG
AADUE
AAEJI
AAEWN
AAGGD
AAGLT
AAGMC
AAJIQ
AAJOX
AAJPV
AAKGS
AANSI
AAPEO
AAPII
AAQDB
AAQXH
AAQXI
AARDL
AARIX
AATAA
AATBZ
AAUAS
AAWTL
AAXOT
AAYTG
AAZBJ
ABAWC
ABAWP
ABCCA
ABCJG
ABDWY
ABEIX
ABFWQ
ABHKI
ABHQH
ABIDT
ABIVO
ABJIS
ABJNI
ABJZC
ABKRH
ABLUO
ABNCE
ABPGX
ABPNF
ABQKF
ABQXT
ABRHV
ABUJY
ABVFX
ABVVC
ABYTW
ACARO
ACDSZ
ACDXX
ACFEJ
ACFMA
ACFYK
ACGBL
ACGFS
ACGZU
ACJER
ACJTF
ACLFY
ACLHI
ACLZU
ACNXM
ACOFE
ACOXC
ACPRK
ACROE
ACRPL
ACSIQ
ACUAV
ACUIR
ACXKE
ACXMB
ADBBV
ADDLC
ADEBD
ADEIA
ADMPF
ADNBR
ADNMO
ADNON
ADRRZ
ADSTG
ADTBJ
ADUKL
ADVBO
ADYCS
ADZYD
ADZZY
AECGH
AECVZ
AEDTQ
AEKYL
AENEX
AEPTA
AEQLS
AERKM
AESZF
AEUHG
AEWDL
AEWHI
AEXFG
AEXNY
AFEET
AFKBI
AFKRG
AFMOU
AFQAA
AFRAH
AFUIA
AFVCE
AFWMB
AGHKR
AGKLV
AGNHF
AGPXR
AGQPQ
AGWFA
AGWNL
AHDMH
AHHFK
AIGRN
AJABX
AJEFB
AJGYC
AJMMQ
AJSCY
AJUZI
AJVBE
AJXAJ
AJXGE
ALKWR
ALMA_UNASSIGNED_HOLDINGS
AMCVQ
ANDLU
ARTOV
ASPBG
AUTPY
AUVAJ
AVWKF
AYAKG
AZFZN
B3H
B8M
B8O
B8R
B8Z
B93
B94
BBRGL
BDDNI
BKIIM
BKSCU
BPACV
BSEHC
BWJAD
BYIEH
C45
CAG
CBRKF
CDWPY
CFDXU
CGR
COF
CORYS
CQQTX
CS3
CUTAK
CUY
CVF
DB0
DC-
DC0
DD-
DD0
DE-
DF0
DO-
DOPDO
DU5
DV7
DV9
D~Y
EBS
ECM
EIF
EJD
EMOBN
F5P
FEDTE
FHBDP
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
H13
HF~
HVGLF
HZ~
IAO
IEA
IHR
INH
INR
IVC
J8X
K.F
K.J
N9A
NPM
O9-
OVD
P.B
P2P
PQQKQ
Q1R
Q7K
Q7L
Q7R
Q7U
Q7X
Q82
Q83
RIG
ROL
S01
SASJQ
SAUOL
SBI
SCNPE
SDB
SFB
SFC
SFK
SFT
SGA
SGO
SGP
SGR
SGV
SGX
SGZ
SHG
SNB
SPJ
SPP
SPQ
SPV
SQCSI
STM
TEORI
UPT
YQT
ZONMY
ZPPRI
ZRKOI
ZSSAH
ZY4
ID FETCH-LOGICAL-c549t-a2e4aace4252fffd5253f34700cba9892b3d86abbd6fe2e9c97f9f76f25dd83f2
IngestDate Mon Jul 21 06:07:00 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords N-methyl-D-aspartate receptor
Ketamine
schizophrenia
glutamate
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c549t-a2e4aace4252fffd5253f34700cba9892b3d86abbd6fe2e9c97f9f76f25dd83f2
PMID 24257811
ParticipantIDs pubmed_primary_24257811
PublicationCentury 2000
PublicationDate 2014-04-01
PublicationDateYYYYMMDD 2014-04-01
PublicationDate_xml – month: 04
  year: 2014
  text: 2014-04-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of psychopharmacology (Oxford)
PublicationTitleAlternate J Psychopharmacol
PublicationYear 2014
SSID ssj0016465
Score 2.5219815
SecondaryResourceType review_article
Snippet The observation that antagonists of the N-methyl-D-aspartate receptor (NMDAR), such as phencyclidine (PCP) and ketamine, transiently induce symptoms of acute...
SourceID pubmed
SourceType Index Database
StartPage 287
SubjectTerms Age of Onset
Animals
Dopamine - metabolism
gamma-Aminobutyric Acid - metabolism
Humans
Ketamine - pharmacology
Phencyclidine - pharmacology
Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors
Schizophrenia - genetics
Schizophrenia - physiopathology
Schizophrenic Psychology
Title Reviewing the ketamine model for schizophrenia
URI https://www.ncbi.nlm.nih.gov/pubmed/24257811
Volume 28
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07T8MwELZ4LCyI9xt5QEyktI7txCPioQoJxFBQt8p2zgIBbQVZ4NdzsZM2FIqAJYpsObL8Xc73PkIOEGOrZWqi2Pqi2ppHhglUVkAr4WRim7ow6F9dy_Ytv-yKbtXDvcwuyU3Dvn-bV_IfVHEMcS2yZP-A7OijOIDviC8-EWF8_grjYNivEp4eIdfPhdDou9v4-MHXekjdFDk05GENxyWsvf8_JBLW7AQXL4P7p4fQOOpyAKPAjDtkEO1BCAn2YThndUNCqx5_AoH5cdmKEhZa6FTckaU1KuB1Vhcuyq8s2DuBUbVTaVr0sS8kCl8BIa8hMnz2kHh9Jw3c9ufZiaLY1dQsmUX1oOh3WhhpSueR5FKMPdLHk1sp6j-Xyyd0CS9TdJbIYgkCPQnILpMZ6K-Qw5sAxdsR7YyT416P6CG9qYG0QhZGl9fbKmmMaIEiLdCKFqinBYpY0k-0sEZuL847p-2o7IURWdTg80gz4FpbwI0z51wmmIhdzJNm0xqtUsVMnKVSG5NJBwyUVYlTLpGOiSxLY8fWyVx_0IdNQgUw1QLTRIab8Qy05gngei10C1QCdotshEPpDUPBk151XNtTZ3bIwpikdsm8wz8M9lBcy82-B-cD_0A-pA
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reviewing+the+ketamine+model+for+schizophrenia&rft.jtitle=Journal+of+psychopharmacology+%28Oxford%29&rft.au=Frohlich%2C+Joel&rft.au=Van+Horn%2C+John+D&rft.date=2014-04-01&rft.eissn=1461-7285&rft.volume=28&rft.issue=4&rft.spage=287&rft_id=info:doi/10.1177%2F0269881113512909&rft_id=info%3Apmid%2F24257811&rft_id=info%3Apmid%2F24257811&rft.externalDocID=24257811